Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares gapped down before the market opened on Wednesday . The stock had previously closed at $4.09, but opened at $3.87. Inventiva shares last traded at $4.09, with a volume of 461,113 shares traded.

Analyst Ratings Changes

Several equities research analysts have issued reports on IVA shares. Truist Financial assumed coverage on shares of Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Finally, Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Down 1.2%

The company has a fifty day simple moving average of $5.40 and a 200-day simple moving average of $5.40.

Inventiva (NASDAQ:IVA) last announced its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter. As a group, equities research analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.8 earnings per share for the current year.

Institutional Trading of Inventiva

Several hedge funds have recently made changes to their positions in IVA. Wealth Enhancement Advisory Services LLC raised its position in shares of Inventiva by 55.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after buying an additional 9,212 shares during the period. Creative Planning purchased a new position in Inventiva in the second quarter worth approximately $32,000. Commonwealth Equity Services LLC grew its position in Inventiva by 19.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock worth $361,000 after acquiring an additional 12,704 shares during the period. Virtu Financial LLC acquired a new stake in Inventiva during the fourth quarter worth $60,000. Finally, XTX Topco Ltd acquired a new stake in Inventiva during the fourth quarter worth $84,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.